Mattia Brugiolo

Mattia Brugiolo

Auto-generated profile, based on publicly available information

Mattia Brugiolo

The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2026 in Science
Verified
Journal Article
Closed access
RERyan Peter Englander
Ryan Peter Englander
MBMattia Brugiolo
Mattia Brugiolo
MDMaëva Devoucoux
Maëva Devoucoux
TWTe-Chia Wu
Te-Chia Wu
MKMitch Kostich
Mitch Kostich
OAOlga Anczukow
Olga Anczukow
Immunotherapy with checkpoint inhibitors has revolutionized cancer therapy and enabled considerable therapeutic advances for treating various diseases, including lung cancer. However, the molecular determinants of variable patient outcomes remain unclear. Using long-read RNA sequencing, we mapped the landscape of alternative RNA splicing in human primary lung adenocarcinomas. We identified more than 149,000 full-length messenger RNA (mRNA) isoforms, more than half of which were unannotated and many that occurred in immune-related genes, particularly within the type I interferon response pathway. We functionally characterized retained introns in the STAT2 gene that produced altered protein isoforms that regulated immune signaling and interferon responses and correlated with patient survival after anti–programmed death-ligand 1 (PD-L1) immunotherapy. These findings position alternative splicing as a regulator of tumor immune responses and reveal intron retention in STAT2 as an interferon regulatory axis that correlates with PD-L1 checkpoint inhibitor response.